Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
Personalized Care

More than 15 million people across Europe have heart failure.1 Help them prevent hospitalizations and reduce mortality risk2 with the CardioMEMS™ HF System, the system that has demonstrated proven benefits in a variety of clinical studies, including four prospective trials studying more than 3,000 people3,4 and three large retrospective studies of more than 5,000 patients.5-7

Prevent Heart Failure Hospitalizations

By remotely managing PA pressure with the CardioMEMS HF System

CardioMEMS System


The CardioMEMS HF System is the only remote monitoring platform for both HFpEF1 and HFrEF patients clinically proven to:

  • Deliver Supportive and intuitive Remote Monitoring
  • Optimize treatment Options To improve Patient Outcomes
  • Increase your Patients’ Quality of Life

As telemedicine becomes more common, the CardioMEMS HF System is a safe, reliable way to help your patients manage their heart failure.

The CardioMEMS HF System offers you real-time notification of patient changes and simple, convenient access to secure data for proactive, personalized patient management. It also provides patients with a heightened awareness of the factors affecting their health and a powerful sense of control.

Deliver Supportive and Intuitive Remote Monitoring

The CardioMEMS HF System promotes seamless, enhanced remote management for your patients. The system integrates a 3-month optimization phase4 that also delivers continuing substantial maintenance support. Intuitive remote monitoring and excellent patient adherence4 with the myCardioMEMS™ app clarifies and enhances patient-clinician communication to streamline the delivery of patient treatment.

One Small Device

The CardioMEMS™ PA Sensor is inserted via a commonly performed right heart catheterization, often as an outpatient procedure. Most patients can return home the same day, and then you’ll have precise and actionable presymptomatic data to inform proactive treatment modifications going forward.

CardioMEMS Flat Sensor

Daily Readings

The patient takes daily readings from wherever they are using the portable CardioMEMS™ Patient Electronics System, giving you a clear picture of their hemodynamic status.

CardioMEMS Sensor

Access To Presymptomatic PA Pressure Data

Patient readings are uploaded remotely to the Merlin.net™ Patient Care Network (PCN), a secure website that easily presents PA pressure data. Based on customizable settings, you can identify patients needing attention, allowing you to intervene before a patient becomes symptomatic.

CardioMEMS Communication Patients

Communication to Patients

If intervention is necessary, you or your team will contact the patient to modify care. In addition to contacting patients via phone or text, the myCardioMEMS™ Mobile App can be used to send patients customizable messages about lifestyle or medication changes.

Communication to Patients

Optimize Treatment Options

To improve patient outcomes

The CardioMEMS™ HF System enables you to provide enhanced, personalized patient care to enrich patients’ lives through the power of data. With the CardioMEMS™ HF System, you can offer a proven reduction of heart failure related hospitalization by up to 82%8, confirming the verified impact on patient outcomes.

Excellent Patient Compliance

Results

Daily Uploads 85.9 ± 19.3%
Weekly Uploads 94.5 ± 14.2%

Patient Compliance Results

Increase Your Patients’ Quality of Life



The CardioMEMS™ HF System’s innovative technology can help transform your heart failure patients’ quality of life and provide increased safety in patient care and management.

In clinical studies, heart failure patients implanted with the CardioMEMS™ HF System showed an important improvement across all surveys (KCCQ, PHQ-9, EQ-5D-5L)4

Reduction in Hospitalizations
MEMS-HF European Study

Improved Quality of Life

Significant improvements across all patient-reported outcomes

Patient Compliance Results

References

  1. Dickstein, K. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29, 2388-2442 (2008).
  2. Setoguchi S, et al. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260-266.
  3. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. The Lancet. 2011;377(9766):658-666.
  4. Angermann C, AßmusB, et al. Pulmonary-Artery-Pressure-Guided Therapy in Ambulatory Patients with Symptomatic Heart Failure: The CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). European J of Heart Failure. 2020. 10.1002/ejhf.1943.
  5. Heywood JT, Jermyn R, Shavelle D, et al. Impact of practice-based management of PA pressures in 2000 patients implanted with the CardioMEMS sensor. Circulation. 2017; 135: 1509–17.
  6. Desai AS, et al. Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in “Real-World” Clinical Practice. J Am Coll Cardiol. 2017; 69(19):2357–65.
  7. Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. JAMA Cardiology. 2019;4(6):556-563.
  8. Cowie MR, Flett A, Cowburn P, et al. Real-world evidence in a national health service: Results of the UK CardioMEMS HF System post-market study. ESC Heart Failure. 2022;9(1):48-56.

MAT-2214006 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.



Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.



Do you want to continue? 

YesNo